GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » HH Biotechnology Holdings Co (OTCPK:HHBT) » Definitions » Debt-to-EBITDA

HHBT (HH Biotechnology Holdings Co) Debt-to-EBITDA : 0.00 (As of Sep. 2016)


View and export this data going back to . Start your Free Trial

What is HH Biotechnology Holdings Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

HH Biotechnology Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. HH Biotechnology Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. HH Biotechnology Holdings Co's annualized EBITDA for the quarter that ended in Sep. 2016 was $9.94 Mil. HH Biotechnology Holdings Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2016 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for HH Biotechnology Holdings Co's Debt-to-EBITDA or its related term are showing as below:

HHBT's Debt-to-EBITDA is not ranked *
in the Real Estate industry.
Industry Median: 6.075
* Ranked among companies with meaningful Debt-to-EBITDA only.

HH Biotechnology Holdings Co Debt-to-EBITDA Historical Data

The historical data trend for HH Biotechnology Holdings Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HH Biotechnology Holdings Co Debt-to-EBITDA Chart

HH Biotechnology Holdings Co Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.06 6.86 7.26 19.60 0.69

HH Biotechnology Holdings Co Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 0.57 0.52 - -

Competitive Comparison of HH Biotechnology Holdings Co's Debt-to-EBITDA

For the Real Estate Services subindustry, HH Biotechnology Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HH Biotechnology Holdings Co's Debt-to-EBITDA Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, HH Biotechnology Holdings Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where HH Biotechnology Holdings Co's Debt-to-EBITDA falls into.



HH Biotechnology Holdings Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

HH Biotechnology Holdings Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.631 + 0) / 6.749
=0.69

HH Biotechnology Holdings Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2016) EBITDA data.


HH Biotechnology Holdings Co  (OTCPK:HHBT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


HH Biotechnology Holdings Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of HH Biotechnology Holdings Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


HH Biotechnology Holdings Co Business Description

Traded in Other Exchanges
N/A
Address
No. 69 Heping North Street, C-Site, 25th - 26th Floor, Presidential Building, Heping District, Shenyang, CHN, 110003
HH Biotechnology Holdings Co is engaged in developing, producing and marketing of healthy food, supplements, medicine, and cosmetics.
Executives
Yizhao Zhang director 45 OLD MILLSTONE DRIVE, NIT 6, EAST WINDSOR NJ 08520

HH Biotechnology Holdings Co Headlines

No Headlines